Skandinaviska Enskilda Banken Ab (Publ) Intellia Therapeutics, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 07, 2023	BUY	$34.58 - $46.03 $111,036 - $147,802	3,211 Added 21.39%	18,223 $743,000
Q1 2023 May 11, 2023	SELL	$33.3 - $44.82 $22,910 - $30,836	-688 Reduced 4.38%	15,012 $559,000
Q4 2022 Feb 08, 2023	SELL	$33.21 - $62.69 $30,187 - $56,985	-909 Reduced 5.47%	15,700 $548,000
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $233,311 - $310,245	4,327 Added 35.23%	16,609 $929,000
Q4 2021 Feb 10, 2022	SELL	$100.76 - $138.36 $7,557 - $10,377	-75 Reduced 0.61%	12,282 $1.49 Million
Q3 2021 Nov 10, 2021	BUY	$132.37 - $176.78 $1.64 Million - $2.18 Million	12,357 New	12,357 $1.66 Million
Q1 2021 May 14, 2021	SELL	$46.59 - $83.68 $1.86 Million - $3.34 Million	-39,935 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$18.83 - $63.53 $6,854 - $23,124	364 Added 0.92%	39,935 $2.17 Million
Q3 2020 Nov 12, 2020	BUY	$17.47 - $24.93 $675,704 - $964,242	38,678 Added 4331.24%	39,571 $787,000
Q2 2020 Aug 13, 2020	BUY	$11.14 - $22.87 $9,948 - $20,422	893 New	893 $19,000

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.